Lv3
220 积分 2022-09-14 加入
An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trial
1个月前
已完结
Parsimonious versus extensive bleeding score: can we simplify risk stratification after percutaneous coronary intervention and reduce bleeding events by de-escalation of the antiplatelet strategy?
1个月前
已关闭
Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome
1个月前
已完结
Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI
1个月前
已完结
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial
1个月前
已完结
Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting
1个月前
已完结
Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI
1个月前
已完结
Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention
1个月前
已完结
Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD
1个月前
已完结
An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial
1个月前
已完结
皖公网安备34019202002308
